The prognostication of TP53 mutations (mut) and deletions (del) was studied in a large cohort of 3307 patients with hematological malignancies: AML (n = 858), MDS (n = 943), ALL (n = 358), CLL (n = 1148) [14]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.